http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102030826-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102030826-B |
| titleOfInvention | High-affinity CD20-resistance monoclonal antibody |
| abstract | The invention discloses a high-affinity CD20-resistance monoclonal antibody and application thereof in preparing antineoplastic drugs. The antibody comprises amino acid substitutions on one or a plurality of amino acid sites of a C2B8 variable region of a heavy chain and / or a variable region of a light chain. Compared with Rituximab, the mutation antibodies have higher affinity activity, the antibody specificity is strengthened, and the lethal effect on the tumor is improved obviously. |
| priorityDate | 2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 138.